## Hiroaki Ikeda

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6229715/publications.pdf

Version: 2024-02-01

		858243	1255698
15	5,369	12	13
papers	citations	h-index	g-index
1.5	1.5	1.5	0227
15	15	15	9237
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors. , 2022, $10$ , e003958.		4
2	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, $10$ , e003811.		26
3	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	2.0	22
4	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Science, 2020, 111, 1958-1968.	1.7	19
5	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	3.9	102
6	T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. International Immunology, 2016, 28, 349-353.	1.8	45
7	Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy, 2016, 8, 527-540.	1.0	10
8	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2268-2277.	3.2	139
9	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Journal of Translational Medicine, 2013, 11, 246.	1.8	94
10	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumorâ€specific CD8 <sup>+</sup> T cells. European Journal of Immunology, 2009, 39, 241-253.	1.6	50
11	Glucocorticoidâ€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€specific CD8 <sup>+</sup> T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	1.7	34
12	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 2009, 27, 6854-6861.	1.7	45
13	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR. Cancer Research, 2009, 69, 9003-9011.	0.4	174
14	Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002, 3, 991-998.	7.0	4,290
15	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. Immunity, 2000, 13, 265-276.	6.6	315